

WHAT IS CLAIMED IS:


1. Use of an effective amount of a compound selected from Formula (I), Formula (II), and Formula (III), or a pharmaceutically acceptable salt of the foregoing, for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound is selected from Formula (I), Formula (II), and Formula (III) has one of the following structures:



(I)





(II)



(III)

wherein:




B^{1A} B^{1B} and B^{1C} are independently an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;




R^{1A} is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid,  and  ;


when the dashed line (------) of Formula (I) is a single bond, R^{2A} is CH_2, and R^{3A} is O (oxygen);

when the dashed line (------) of Formula (I) is absent, R^{2A} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6}

alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano, and R^{3A} is selected from the group consisting of OH, $-OC(=O)R''^{A}$ and an optionally substituted O-linked amino acid;

R^{1B} is selected from the group consisting of O^-, OH,  ,  ,  , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{1C} and R^{2C} are independently selected from the group consisting of O^-, OH, an optionally substituted C_{1-6} alkoxy,  ,  ,  , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; or






R^{1C} is  and R^{2C} is O^- or OH;


R^{2B} and R^{3C} are independently selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano;

R^{4C} is selected from the group consisting of OH, $-OC(=O)R''^{C}$ and an optionally substituted O-linked amino acid;



R^{4A}, R^{3B} and R^{5C} are independently a halogen;

R^{5A}, R^{4B} and R^{6C} are independently hydrogen or halogen;

R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted *–$(CR^{15A}R^{16A})_p$–O–C_{1-24} alkyl, an optionally substituted *–$(CR^{17A}R^{18A})_q$–O–C_{1-24} alkenyl,  ,  ,  ,  and  or



R^{6A} is absent or hydrogen; or

R^{6A} and R^{7A} are taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally substituted  , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system;.

R^{9A} is independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, $NR^{30A}R^{31A}$, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{10A} and R^{11A} are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

each R^{15A}, each R^{16A}, each R^{17A} and each R^{18A} are independently hydrogen, an optionally substituted C_{1-24} alkyl or alkoxy;

R^{19A}, R^{20A}, R^{22A}, R^{23A}, R^{5B}, R^{6B}, R^{8B}, R^{9B}, R^{9C}, R^{10C}, R^{12C} and R^{13C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{21A}, R^{24A}, R^{7B}, R^{10B}, R^{11C} and R^{14C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl and an optionally substituted –O–aryl;

R^{25A}, R^{29A}, R^{11B} and R^{15C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{16C}, R^{17C} and R^{18C} are independently absent or hydrogen;

R^{26A} and R^{27A} are independently -C≡N or an optionally substituted substituent selected from the group consisting of C_{2-8} organylcarbonyl, C_{2-8} alkoxycarbonyl and C_{2-8} organylaminocarbonyl;

R^{28A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

R^{30A} and R^{31A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

for Formula (III), ------- is a single bond or a double bond;

when ------- is a single bond, each R^{7C} and each R^{8C} is independently hydrogen or halogen; and

when ------- is a double bond, each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen;

$R^{''A}$ and $R^{''C}$ are independently an optionally substituted C_{1-24}-alkyl;


m and n are independently 0 or 1;

p and q are independently selected from the group consisting of 1, 2 and 3;

r is 1 or 2;

Z^{1A}, Z^{2A}, Z^{3A}, Z^{4A}, Z^{1B}, Z^{2B} and Z^{1C} are independently O or S; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is




R^{9A} wherein R^{8A} is an unsubstituted C_{1-4} alkyl or phenyl optionally para-substituted with a halogen or methyl and R^{9A} is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro or hydrogen; and B^{1A} is an unsubstituted uracil; then R^{2A} cannot be $-OCH_3$;

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be allenyl;


provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is hydrogen; and B^{1A} is an unsubstituted thymine; then R^{2A} cannot be C_1 alkyl substituted with an N-amido; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be ethynyl.


2. A method for ameliorating or treating a viral infection caused by a virus comprising administering to or contacting a cell in a subject with an effective amount of a compound selected from Formula (I), Formula (II), and Formula (III), or a pharmaceutically acceptable salt of the foregoing, wherein the virus is selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, and wherein the compound is selected from Formula (I), Formula (II), and Formula (III) has one of the following structures:



(I)





(II)



(III)




wherein:




B^{1A} B^{1B} and B^{1C} are independently an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;


R^{1A} is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid,  , and  ;

when the dashed line (------) of Formula (I) is a single bond, R^{2A} is CH_2, and R^{3A} is O (oxygen);

when the dashed line (------) of Formula (I) is absent, R^{2A} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano, and R^{3A} is selected from the group consisting of OH, $-OC(=O)R''^{A}$ and an optionally substituted O-linked amino acid;

R^{1B} is selected from the group consisting of O^-, OH,  ,  ,  , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{1C} and R^{2C} are independently selected from the group consisting of O^-, OH, an optionally substituted C_{1-6} alkoxy,  ,  ,  , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; or



R^{1C} is and R^{2C} is O^- or OH;







R^{2B} and R^{3C} are independently selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano;

R^{4C} is selected from the group consisting of OH, $-OC(=O)R^{"C}$ and an optionally substituted O-linked amino acid;



R^{4A}, R^{3B} and R^{5C} are independently a halogen;

R^{5A}, R^{4B} and R^{6C} are independently hydrogen or halogen;

R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted $*-(CR^{15A}R^{16A})_p-O-C_{1-24}$ alkyl, an optionally substituted $*-(CR^{17A}R^{18A})_q-O-C_{1-24}$

alkenyl,  ,  ,  ,  and  ; or 

R^{6A} is m and R^{7A} is absent or hydrogen; or

R^{6A} and R^{7A} are taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally substituted  , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system;.

R^{9A} is independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, $NR^{30A}R^{31A}$, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{10A} and R^{11A} are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

each R^{15A}, each R^{16A}, each R^{17A} and each R^{18A} are independently hydrogen, an optionally substituted C_{1-24} alkyl or alkoxy;

R^{19A}, R^{20A}, R^{22A}, R^{23A}, R^{5B}, R^{6B}, R^{8B}, R^{9B}, R^{9C}, R^{10C}, R^{12C} and R^{13C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{21A}, R^{24A}, R^{7B}, R^{10B}, R^{11C} and R^{14C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl and an optionally substituted –O–aryl;

R^{25A}, R^{29A}, R^{11B} and R^{15C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{16C}, R^{17C} and R^{18C} are independently absent or hydrogen;

R^{26A} and R^{27A} are independently -C≡N or an optionally substituted substituent selected from the group consisting of C_{2-8} organylcarbonyl, C_{2-8} alkoxycarbonyl and C_{2-8} organylaminocarbonyl;

R^{28A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

R^{30A} and R^{31A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

for Formula (III), ------- is a single bond or a double bond;

when ------- is a single bond, each R^{7C} and each R^{8C} is independently hydrogen or halogen; and

when ------- is a double bond, each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen;

R^{29A} and R^{29C} are independently an optionally substituted C_{1-24}-alkyl;


m and n are independently 0 or 1;

p and q are independently selected from the group consisting of 1, 2 and 3;

r is 1 or 2;

Z^{1A}, Z^{2A}, Z^{3A}, Z^{4A}, Z^{1B}, Z^{2B} and Z^{1C} are independently O or S; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is



wherein R^{8A} is an unsubstituted C_{1-4} alkyl or phenyl optionally para-substituted with a halogen or methyl and R^{9A} is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and

proline; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro or hydrogen; and B^{1A} is an unsubstituted uracil; then R^{2A} cannot be $-OCH_3$;

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be allenyl;

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is hydrogen; and B^{1A} is an unsubstituted thymine; then R^{2A} cannot be C_1 alkyl substituted with an N-amido; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be ethynyl.

3. The use of Claim 1 or the method of Claim 2, wherein the virus is a henipavirus.

4. The use or method of Claim 3, wherein the henipavirus is a nipahvirus.

5. The use of Claim 1 or the method of Claim 2, wherein the virus is a morbillivirus.

6. The use or method of Claim 5, wherein the morbillivirus is the measles virus.

7. The use of Claim 1 or the method of Claim 2, wherein the virus is a respirovirus.

8. The use or method of Claim 7, wherein the respirovirus is human parainfluenza virus 1.

9. The use or method of Claim 7, wherein the respirovirus is human parainfluenza virus 3.

10. The use of Claim 1 or the method of Claim 2, wherein the virus is a rubulavirus.

11. The use or method of Claim 10, wherein the rubulavirus is the mumps virus.


12. The use or method of Claim 10, wherein the rubulavirus is human parainfluenza virus 2.

13. The use or method of Claim 10, wherein the rubulavirus is human parainfluenza virus 4.

14. The use of Claim 1 or the method of Claim 2, wherein the virus is a metapneumovirus.

15. The use or method of Claim 14, wherein the metaphenumovirus is human metapneumovirus.

16. The use of any one of Claim 1 or 3-15 or the method of any one of Claims 2-15, wherein the compound is a compound of Formula (I).

17. The use or method of Claim 16, wherein R^{1A} is  .

18. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both hydrogen.




19. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both absent.




20. The use or method of Claim 17, wherein one of R^{6A} and R^{7A} is hydrogen, and the other of R^{6A} and R^{7A} is selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl).

21. The use or method of Claim 20, wherein the other of R^{6A} and R^{7A} is an optionally substituted C_{1-24} alkyl.

22. The use or method of Claim 17, wherein both R^{6A} and R^{7A} are independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl).

23. The use or method of Claim 22, wherein both R^{6A} and R^{7A} are an optionally substituted C_{1-24} alkyl.

24. The use or method of Claim 17, wherein at least one of R^{6A} and R^{7A} are selected from the group consisting of  ,  ,  and  ; and the other of R^{6A} and R^{7A} is selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl).

25. The use or method of Claim 17, wherein both R^{6A} and R^{7A} are independently selected from the group consisting of  ,  ,  and .

26. The use or method of any one of Claims 24-25, wherein both R^{26A} and R^{27A} are an optionally substituted C_{2-8} organylcarbonyl.


27. The use or method of Claim 26, wherein the optionally substituted C_{1-8} organylcarbonyl is $-C(=O)CH_3$.


28. The use or method of any one of Claims 24-25, wherein both R^{26A} and R^{27A} are an optionally substituted C_{2-8} alkoxycarbonyl.

29. The use or method of Claim 28, wherein the optionally substituted C_{1-8} alkoxycarbonyl is $-C(=O)OCH_2CH_3$.

30. The use or method of Claim 28, wherein the optionally substituted C_{1-8} alkoxycarbonyl is $-C(=O)OCH_3$.

31. The use or method of any one of Claims 24-30, wherein R^{28A} is an optionally substituted C_{1-4}-alkyl

32. The use or method of any one of Claims 24-25, wherein  is selected from the group consisting of:



and

33. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both an optionally substituted C_{1-24} alkyl.


34. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both an optionally substituted C_{2-24} alkenyl.


35. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both $*-(CR^{15A}R^{16A})_n-O-C_{1-24}$ alkyl.


36. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both $*-(CR^{17A}R^{18A})_q-O-C_{2-24}$ alkenyl.


37. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both an optionally substituted aryl.


38. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both an optionally substituted aryl(C_{1-6} alkyl).



39. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both  .






40. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both  .

41. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both  .

42. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both  .


43. The use or method of Claim 17, wherein R^{6A} and R^{7A} are both  .

44. The use or method of Claim 17, wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally substituted  , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system.

45. The use or method of Claim 44, wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of  ,  ,  ,  and  , wherein R^{32A} is an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

46. The use or method of any one of Claims 17-45, wherein Z^{1A} is O.

47. The use or method of any one of Claims 17-45, wherein Z^{1A} is S.

48. The use or method of Claim 16, wherein R^{1A} is  .

49. The use or method of Claim 48, wherein R^{8A} is selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl; and R^{9A} is independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl.

50. The use or method of Claim 49, wherein R^{8A} is hydrogen, and R^{9A} is an optionally substituted C_{1-6} alkyl.

51. The use or method of Claim 48, wherein R^{8A} is hydrogen, and R^{9A} is $NR^{30A}R^{31A}$, wherein R^{30} and R^{31} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl.


52. The use or method of Claim 48, wherein R^{8A} is absent or hydrogen; and R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

53. The use or method of Claim 48, wherein R^{8A} is an optionally substituted aryl; and R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

54. The use or method of Claim 52 or 53, wherein R^{9A} is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof.

55. The use or method of Claim 54, wherein R^{9A} is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester.

56. The use or method of Claim 52 or 53, wherein R^{9A} has the structure



wherein R^{33A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{34A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{35A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{34A} and R^{35A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

57. The use or method of Claim 56, wherein R^{34A} is an optionally substituted C_{1-6}-alkyl.


58. The use or method of Claim 57, wherein the optionally substituted C_{1-6}-alkyl is methyl.

59. The use or method of any one of Claims 56-58, wherein R^{35A} is hydrogen.

60. The use or method of any one of Claims 56-59, wherein R^{33A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

61. The use or method of any one of Claims 48-60, wherein Z^{2A} is O.


62. The use or method of any one of Claims 48-60, wherein Z^{2A} is S.

63. The use or method of Claim 16, wherein R^{1A} is  .

64. The use or method of Claim 63, wherein R^{10A} and R^{11A} are both an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

65. The use or method of Claim 64, wherein R^{10A} and R^{11A} are independently selected from selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof.

66. The use or method of Claim 65, wherein R^{10A} and R^{11A} are independently selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester.

67. The use or method of Claim 64, wherein R^{10A} and R^{11A} are independently have the structure  wherein R^{36A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{37A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{38A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{37A} and R^{38A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

68. The use or method of Claim 67, wherein R^{37A} is an optionally substituted C_{1-6}-alkyl.


69. The use or method of Claim 68, wherein the optionally substituted C_{1-6}-alkyl is methyl.

70. The use or method of any one of Claims 67-69, wherein R^{38A} is hydrogen.

71. The use or method of any one of Claims 67-70, wherein R^{36A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

72. The use or method of any one of Claims 63-71, wherein Z^{3A} is O.

73. The use or method of any one of Claims 63-71, wherein Z^{3A} is S.



74. The use or method of Claim 16, wherein R^{6A} is and R^{7A} is absent or hydrogen; wherein R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.

75. The use or method of Claim 74, wherein m is 0, and R^{12A} and R^{13A} are independently absent or hydrogen.

76. The use or method of Claim 74, wherein m is 1, and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.


77. The use or method of Claim 16, wherein R^{1A} is H.

78. The use or method of Claim 16, wherein R^{1A} is an optionally substituted acyl.

79. The use or method of Claim 78, wherein the optionally substituted acyl is $-C(=O)R^{39A}$, wherein R^{39A} is selected from the group consisting of an optionally substituted C_{1-12} alkyl, an optionally substituted C_{2-12} alkenyl, an optionally substituted C_{2-12} alkynyl, an optionally substituted C_{3-8} cycloalkyl, an optionally substituted C_{5-8} cycloalkenyl, an optionally substituted C_{6-10} aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl).

80. The use or method of Claim 79, wherein R^{39A} is substituted or unsubstituted C_{1-12} alkyl.

81. The use or method of Claim 16, wherein R^{1A} is an optionally substituted O-linked amino acid.


82. The use or method of Claim 16, wherein R^{1A} is  , wherein R^{40A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{41A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{40A} and R^{41A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

83. The use or method of Claim 82, wherein R^{40A} is an optionally substituted C_{1-6}-alkyl.

84. The use or method of Claim 83, wherein the optionally substituted C_{1-6}-alkyl is methyl.

85. The use or method of any one of Claims 82-84, wherein R^{41A} is hydrogen.

86. The use or method of any one of Claims 16-85, wherein B^{1A} is selected from the group consisting of:



and ;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is selected from the group consisting of hydrogen, $-C(=O)R^{K2}$ and $-C(=O)OR^{L2}$;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{M2}$ and $-C(=O)OR^{N2}$;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is selected from the group consisting of hydrogen, $-C(=O)R^{P2}$ and $-C(=O)OR^{Q2}$;

R^{D2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{E2} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{R2}$ and $-C(=O)OR^{S2}$;


R^{F2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;


Y^2 and Y^3 are independently N or CR^{I2}, wherein R^{I2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;


R^{G2} is an optionally substituted C_{1-6} alkyl;


R^{II2} is hydrogen or NHR^{T2}, wherein R^{T2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{U2}$ and $-C(=O)OR^{V2}$; and


R^{K2}, R^{L2}, R^{M2}, R^{N2}, R^{P2}, R^{Q2} R^{R2}, R^{S2}, R^{U2} and R^{V2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heteroalicyclyl(C_{1-6} alkyl).


87. The use or method of Claim 86, wherein B^{1A} is  .

88. The use or method of Claim 86, wherein B^{1A} is  .

89. The use or method of Claim 86, wherein B^{1A} is  .

90. The use or method of Claim 86, wherein B^{1A} is  .

91. The use or method of Claim 86, wherein B^{1A} is  .

92. The use or method of Claim 86, wherein B^{1A} is  .

93. The use or method of any one of Claims 16-92, wherein the dashed line (------) is a single bond, R^{2A} is CH_2, and R^{3A} is O.

94. The use or method of any one of Claims 16-92, wherein the dashed line (------) is absent, R^{2A} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano, and R^{3A} is selected from the group consisting of OH, $-OC(=O)R^{7A}$ and an optionally substituted O-linked amino acid.

95. The use or method of Claim 94, wherein R^{2A} is an optionally substituted C_{1-6} alkyl.

96. The use or method of Claim 95, wherein R^{2A} is unsubstituted C_{1-6} alkyl.

97. The use or method of Claim 94, wherein R^{2A} is an optionally substituted C_{2-6} alkenyl.

98. The use or method of Claim 97, wherein R^{2A} is unsubstituted C_{2-6} alkenyl.

99. The use or method of Claim 94, wherein R^{2A} is an optionally substituted C_{2-6} alkynyl.

100. The use or method of Claim 99, wherein R^{2A} is unsubstituted C_{2-6} alkynyl.

101. The use or method of Claim 94, wherein R^{2A} is an optionally substituted C_{3-6} cycloalkyl.

102. The use or method of Claim 94, wherein R^{2A} is an optionally substituted $-O-C_{1-6}$ alkyl.

103. The use or method of Claim 102, wherein R^{2A} is unsubstituted $-O-C_{1-6}$ alkyl.

104. The use or method of Claim 94, wherein R^{2A} is an optionally substituted $-O-C_{3-6}$ alkenyl.

105. The use or method of Claim 104, wherein R^{2A} is unsubstituted $-O-C_{3-6}$ alkenyl.

106. The use or method of Claim 94, wherein R^{2A} is an optionally substituted $-O-C_{3-6}$ alkynyl.

107. The use or method of Claim 106, wherein R^{2A} is unsubstituted $-O-C_{3-6}$ alkynyl.

108. The use or method of Claim 94, wherein R^{2A} is cyano.

109. The use or method of any one of Claims 94-108, wherein R^{3A} is OH.


110. The use or method of any one of Claims 94-108, wherein R^{3A} is $-OC(=O)R^{"A}$.

111. The use or method of Claim 110, wherein $R^{"A}$ is an optionally substituted C_{1-8} alkyl.

112. The use or method of any one of Claims 94-108, wherein R^{3A} is O-linked amino acid.

113. The use or method of Claim 112, wherein the O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine.

114. The use or method of any one of Claims 94-108, wherein R^{3A} is



, wherein R^{42A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{43A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{42A} and R^{43A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

115. The use or method of Claim 114, wherein R^{42A} is an optionally substituted C_{1-6}-alkyl.

116. The use or method of Claim 115, wherein the optionally substituted C_{1-6}-alkyl is methyl.

117. The use or method of any one of Claims 114-116, wherein R^{43A} is hydrogen.

118. The use or method of any one of Claims 16- 117, wherein R^{5A} is hydrogen.

119. The use or method of any one of Claims 16-117, wherein R^{5A} is halogen.


120. The use or method of Claim 119, wherein R^{5A} is fluoro.


121. The use or method of any one of Claims 16-120, wherein R^{4A} is fluoro.


122. The use of any one of Claim 1 or 3-15 or the method of any one of Claims 2-15, wherein the compound is a compound of Formula (II).

123. The use or method of Claim 122, wherein R^{1B} is O^- or OH.

124. The use or method of Claim 122, wherein R^{1B} is




125. The use or method of Claim 122, wherein R^{1B} is  .

126. The use or method of Claim 122, wherein R^{1B} is  .

127. The use or method of Claim 122, wherein R^{1B} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

128. The use or method of Claim 127, wherein R^{1B} is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof.

129. The use or method of Claim 128, wherein R^{1B} is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester.

130. The use or method of Claim 127, wherein R^{1B} has the structure  wherein R^{12B} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{13B} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{14B} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{13B} and R^{14B} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

131. The use or method of Claim 130, wherein R^{13B} is an optionally substituted C_{1-6}-alkyl.

132. The use or method of Claim 131, wherein the optionally substituted C_{1-6}-alkyl is methyl.

133. The use or method of any one of Claims 130-132, wherein R^{14B} is hydrogen.

134. The use or method of any one of Claims 130-133, wherein R^{12B} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

135. The use or method of any one of Claims 122-134, wherein R^{2B} is an optionally substituted C_{1-6} alkyl.

136. The use or method of Claim 135, wherein R^{2B} is unsubstituted C_{1-6} alkyl.

137. The use or method of any one of Claims 122-134, wherein R^{2B} is an optionally substituted C_{2-6} alkenyl.

138. The use or method of Claim 137, wherein R^{2B} is unsubstituted C_{2-6} alkenyl.

139. The use or method of any one of Claims 122-134, wherein R^{2B} is an optionally substituted C_{2-6} alkynyl.

140. The use or method of Claim 139, wherein R^{2B} is unsubstituted C_{2-6} alkynyl.

141. The use or method of any one of Claims 122-134, wherein R^{2B} is an optionally substituted $-O-C_{1-6}$ alkyl.

142. The use or method of Claim 141, wherein R^{2B} is unsubstituted $-O-C_{1-6}$ alkyl.

143. The use or method of any one of Claims 122-134, wherein R^{2B} is an optionally substituted $-O-C_{3-6}$ alkenyl.

144. The use or method of Claim 143, wherein R^{2B} is unsubstituted $-O-C_{3-6}$ alkenyl.

145. The use or method of any one of Claims 122-134, wherein R^{2B} is an optionally substituted $-O-C_{3-6}$ alkynyl.

146. The use or method of Claim 145, wherein R^{2B} is unsubstituted $-O-C_{3-6}$ alkynyl.

147. The use or method of any one of Claims 122-134, wherein R^{2B} is an optionally substituted C_{3-6} cycloalkyl.

148. The use or method of any one of Claims 122-134, wherein R^{2B} is cyano.

149. The use or method of any one of Claims 122-148, wherein R^{4B} is hydrogen.

150. The use or method of any one of Claims 122-148, wherein R^{4B} is halogen.


151. The use or method of Claim 150, wherein R^{4B} is fluoro.

152. The use or method of any one of Claims 122-151, wherein R^{3B} is fluoro.

153. The use or method of any one of Claims 122-152, wherein Z^{1B} is O.

154. The use or method of any one of Claims 122-152, wherein Z^{1B} is S.

155. The use or method of any one of Claims 122-154, wherein B^{1B} is selected from the group consisting of:



wherein:

R^{AB2} is selected from the group consisting of hydrogen, halogen and NHR^{JB2}, wherein R^{JB2} is selected from the group consisting of hydrogen, $-C(=O)R^{KB2}$ and $-C(=O)OR^{LB2}$;

R^{BB2} is halogen or NHR^{WB2}, wherein R^{WB2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{MB2}$ and $-C(=O)OR^{NB2}$;

R^{CB2} is hydrogen or NHR^{OB2}, wherein R^{OB2} is selected from the group consisting of hydrogen, $-C(=O)R^{PB2}$ and $-C(=O)OR^{QB2}$;

R^{DB2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{EB2} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{RB2}$ and $-C(=O)OR^{SB2}$;


R^{FB2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;


Y^{2B} and Y^{3B} are independently N or CR^{IB2}, wherein R^{IB2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;


R^{GB2} is an optionally substituted C_{1-6} alkyl;


R^{HB2} is hydrogen or NHR^{TB2}, wherein R^{TB2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{UB2}$ and $-C(=O)OR^{VB2}$; and


R^{KB2}, R^{LB2}, R^{MB2}, R^{NB2}, R^{PB2}, R^{QB2} R^{RB2}, R^{SB2}, R^{UB2} and R^{VB2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heteroalicyclyl(C_{1-6} alkyl).


156. The use or method of Claim 155, wherein B^{1B} is  .

157. The use or method of Claim 155, wherein B^{1B} is  .

158. The use or method of Claim 155, wherein B^{1B} is  .

159. The use or method of Claim 155, wherein B^{1B} is  .


160. The use or method of Claim 155, wherein B^{1B} is  .

161. The use or method of Claim 155, wherein B^{1B} is  .


162. The use of any one of Claim 1 or 3-15 or the method of any one of Claims 2-15, wherein the compound is a compound of Formula (III).

163. The use or method of Claim 162, wherein R^{1C} is O^- or OH.


164. The use or method of Claim 162, wherein R^{1C} is an optionally substituted C_{1-6} alkoxy.



165. The use or method of Claim 162, wherein R^{1C} is



166. The use or method of Claim 162, wherein R^{1C} is



167. The use or method of Claim 162, wherein R^{1C} is


168. The use or method of Claim 162, wherein R^{1C} is an optionally substituted N-linked amino acid.

169. The use or method of Claim 162, wherein R^{1C} is an optionally substituted N-linked amino acid ester derivative.


170. The use or method of any one of Claims 162-169, wherein R^{2C} is O^- or OH.

171. The use or method of any one of Claims 162-169, wherein R^{2C} is an optionally substituted C_{1-6} alkoxy.


172. The use or method of any one of Claims 162-169, wherein R^{2C} is



173. The use or method of any one of Claims 162-169, wherein R^{2C} is




174. The use or method of any one of Claims 162-169, wherein R^{2C} is



175. The use or method of any one of Claims 162-169, wherein R^{2C} is an optionally substituted N-linked amino acid.

176. The use or method of any one of Claims 162-169, wherein R^{2C} is an optionally substituted N-linked amino acid ester derivative.

177. The use or method of any one of Claim 176, wherein R^{1C} is  and R^{2C} is O^- or OH; wherein R^{16C}, R^{17C} and R^{18C} is absent or hydrogen; and n is 0 or 1.

178. The use or method of any one of Claims 162-177, wherein R^{3C} is an optionally substituted C_{1-6} alkyl.

179. The use or method of Claim 178, wherein R^{3C} is unsubstituted C_{1-6} alkyl.

180. The use or method of any one of Claims 162-177, wherein R^{3C} is an optionally substituted C_{2-6} alkenyl.

181. The use or method of Claim 180, wherein R^{3C} is unsubstituted C_{2-6} alkenyl.

182. The use or method of any one of Claims 162-177, wherein R^{3C} is an optionally substituted C_{2-6} alkynyl.

183. The use or method of Claim 182, wherein R^{3C} is unsubstituted C_{2-6} alkynyl.

184. The use or method of any one of Claims 162-177, wherein R^{3C} is an optionally substituted $-O-C_{1-6}$ alkyl.

185. The use or method of Claim 184, wherein R^{3C} is unsubstituted $-O-C_{1-6}$ alkyl.

186. The use or method of any one of Claims 162-177, wherein R^{3C} is an optionally substituted $-O-C_{3-6}$ alkenyl.

187. The use or method of Claim 186, wherein R^{3C} is unsubstituted $-O-C_{3-6}$ alkenyl.

188. The use or method of any one of Claims 162-177, wherein R^{3C} is an optionally substituted $-O-C_{3-6}$ alkynyl.

189. The use or method of Claim 188, wherein R^{3C} is unsubstituted $-O-C_{3-6}$ alkynyl.

190. The use or method of any one of Claims 162-177, wherein R^{3C} is an optionally substituted C_{3-6} cycloalkyl.

191. The use or method of any one of Claims 162-177, wherein R^{3C} is cyano.


192. The use or method of any one of Claims 162-191, wherein R^{4C} is OH.

193. The use or method of any one of Claims 162-191, wherein R^{4C} is $-OC(=O)R^{"C}$.

194. The use or method of Claim 193, wherein $R^{"C}$ is an optionally substituted C_{1-8} alkyl.

195. The use or method of any one of Claims 162-191, wherein R^{4C} is O-linked amino acid.

196. The use or method of Claim 195, wherein the O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine.

197. The use or method of any one of Claims 162-191, wherein R^{4C} is  , wherein R^{22C} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{23C} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{22C} and R^{23C} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

198. The use or method of Claim 197, wherein R^{22C} is an optionally substituted C_{1-6}-alkyl.


199. The use or method of Claim 198, wherein the optionally substituted C_{1-6}-alkyl is methyl.

200. The use or method of any one of Claims 197-199, wherein R^{23C} is hydrogen.

201. The use or method of any one of Claims 162-200, wherein R^{6C} is halogen.

202. The use or method of any one of Claims 162-200, wherein R^{6C} is hydrogen.


203. The use or method of any one of Claims 162-202, wherein R^{5C} is fluoro.

204. The use or method of any one of Claims 162-203, wherein ------ is a single bond such that Formula (II) has the structure  , wherein each R^{7C} and each R^{8C} is independently hydrogen or halogen.

205. The use or method of Claim 204, wherein the R^{7C} and the R^{8C} groups are all hydrogen.

206. The use or method of Claim 204, wherein one R^{7C} is halogen, one R^{7C} is hydrogen and both R^{8C} groups are all hydrogen.

207. The use or method of Claim 204, wherein one R^{7C} is halogen, one R^{7C} is hydrogen, one R^{8C} is halogen and one R^{8C} is hydrogen.


208. The use or method of any one of Claims 162-203, wherein ------- is a double bond such that Formula (III) has the structure  , wherein each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen.

209. The use or method of Claim 208, wherein both R^{8C} groups are hydrogen.

210. The use or method of Claim 208, wherein one R^{8C} is halogen and the other R^{8C} is hydrogen.

211. The use or method of Claim 208, wherein both R^{8C} groups are halogen.

212. The use or method of any one of Claims 162-211, wherein B^{1C} is selected from the group consisting of:



wherein:

R^{AC2} is selected from the group consisting of hydrogen, halogen and NHR^{JC2}, wherein R^{JC2} is selected from the group consisting of hydrogen, $-C(=O)R^{KC2}$ and $-C(=O)OR^{LC2}$;

R^{BC2} is halogen or NHR^{WC2}, wherein R^{WC2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{MC2}$ and $-C(=O)OR^{NC2}$;

R^{CC2} is hydrogen or NHR^{OC2}, wherein R^{OC2} is selected from the group consisting of hydrogen, $-C(=O)R^{PC2}$ and $-C(=O)OR^{QC2}$;

R^{DC2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{EC2} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{RC2}$ and $-C(=O)OR^{SC2}$;


R^{FC2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;


Y^{2C} and Y^{3C} are independently N or CR^{IC2}, wherein R^{IC2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;


R^{GC2} is an optionally substituted C_{1-6} alkyl;


R^{HC2} is hydrogen or NHR^{TC2}, wherein R^{TC2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{UC2}$ and $-C(=O)OR^{VC2}$; and


R^{KC2}, R^{LC2}, R^{MC2}, R^{NC2}, R^{PC2}, R^{QC2} R^{RC2}, R^{SC2}, R^{UC2} and R^{VC2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heteroalicyclyl(C_{1-6} alkyl).


213. The use or method of Claim 212, wherein B^{1C} is  .

214. The use or method of Claim 212, wherein B^{1C} is  .


215. The use or method of Claim 212, wherein B^{1C} is  .




216. The use or method of Claim 212, wherein B^{1C} is  .

217. The use or method of Claim 212, wherein B^{1C} is  .













218. The use or method of Claim 212, wherein B^{1C} is  .

219. The use or method of Claim 16, wherein the compound of Formula (I) is selected from the group consisting of:










and

, or a pharmaceutically acceptable salt of the foregoing.


220. The use or method of Claim 16, wherein the compound of Formula (I) is selected from the group consisting of:












and

, or a pharmaceutically acceptable salt of the foregoing.








221. The use or method of Claim 16, wherein the compound of Formula (I) is selected from the group consisting of:





and

, or a pharmaceutically acceptable salt of the foregoing.
















222. The use or method of Claim 16, wherein the compound of Formula (I) is

, or a pharmaceutically acceptable salt thereof.













223. The use or method of Claim 16, wherein the compound of Formula (I) is

, or a pharmaceutically acceptable salt thereof.

224. The use or method of Claim 16, wherein the compound of Formula (I) is selected from the group consisting of:


































,

,

,

,

,

,

,

,

,

,

,

,





298



,

,

and

, or a pharmaceutically acceptable salt of the foregoing.


225. The use or method of Claim 16, wherein the compound of Formula (I) is selected from the group consisting of:



and

, or a pharmaceutically acceptable salt of the foregoing.


226. The use or method of Claim 16, wherein the compound of Formula (I) is selected from the group consisting of:



,

,

,

,



































































,

,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.


227. The use or method of Claim 16, wherein the compound of Formula (I) is selected from the group consisting of:



,

,

,

,



,

,

,

,

,

,

,

,

,

,






































,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

228. The use or method of Claim 122, wherein the compound of Formula (II) is

, or a pharmaceutically acceptable salt thereof.

229. The use or method of Claim 122, wherein the compound of Formula (II) is selected from the group consisting of:




and




, or a pharmaceutically acceptable salt of the foregoing.


230. The use or method of Claim 162, wherein the compound of Formula (III) is selected from the group consisting of:




,




,




,





,







,



,



and

, or a pharmaceutically acceptable salt of the foregoing.

231. The use or method of Claim 162, wherein the compound of Formula (III) is selected from the group consisting of:



,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

CLAIMS


1. Use of an effective amount of a compound selected from Formula (I), Formula (II), and Formula (III), or a pharmaceutically acceptable salt of the foregoing, in the preparation of a medicine for ameliorating or treating a viral infection caused by a virus selected from a henipavirus, a morbillivirus, a respirovirus, a rubulavirus and a metapneumovirus, wherein the compound is selected from Formula (I), Formula (II), and Formula (III) has one of the following structures:



(I)






(II)



(III)




wherein:




B^{1A} B^{1B} and B^{1C} are independently an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;


R^{1A} is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid,  ,  and  ;

when the dashed line (------) of Formula (I) is a single bond, R^{2A} is CH_2, and R^{3A} is O (oxygen);

when the dashed line (------) of Formula (I) is absent, R^{2A} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano, and R^{3A} is selected from the group consisting of OH, $-OC(=O)R''^{A}$ and an optionally substituted O-linked amino acid;

R^{1B} is selected from the group consisting of O^-, OH,  ,  ,  , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{1C} and R^{2C} are independently selected from the group consisting of O^-, OH, an optionally substituted C_{1-6} alkoxy,  ,  ,  , an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; or

R^{1C} is  and R^{2C} is O^- or OH;






R^{2B} and R^{3C} are independently selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted $-O-C_{1-6}$ alkyl, an optionally substituted $-O-C_{3-6}$ alkenyl, an optionally substituted $-O-C_{3-6}$ alkynyl and cyano;


R^{4C} is selected from the group consisting of OH, $-OC(=O)R^{"C}$ and an optionally substituted O-linked amino acid;



R^{4A}, R^{3B} and R^{5C} are independently a halogen;

R^{5A}, R^{4B} and R^{6C} are independently hydrogen or halogen;

R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted *–$(CR^{15A}R^{16A})_p$–O–C_{1-24} alkyl, an optionally substituted *–$(CR^{17A}R^{18A})_q$–O–C_{1-24} alkenyl,


,

,

,

and

; or

R^{6A} is

and R^{7A} is absent or hydrogen; or

R^{6A} and R^{7A} are taken together to form a moiety selected from the group consisting of an optionally substituted

and an optionally substituted

,
wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system;.

R^{9A} is independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl,

$NR^{30A}R^{31A}$, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;

R^{10A} and R^{11A} are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative;

R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen;

each R^{15A}, each R^{16A}, each R^{17A} and each R^{18A} are independently hydrogen, an optionally substituted C_{1-24} alkyl or alkoxy;

R^{19A}, R^{20A}, R^{22A}, R^{23A}, R^{5B}, R^{6B}, R^{8B}, R^{9B}, R^{9C}, R^{10C}, R^{12C} and R^{13C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{21A}, R^{24A}, R^{7B}, R^{10B}, R^{11C} and R^{14C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted aryl, an optionally substituted –O–C_{1-24} alkyl and an optionally substituted –O–aryl;

R^{25A}, R^{29A}, R^{11B} and R^{15C} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted aryl;

R^{16C}, R^{17C} and R^{18C} are independently absent or hydrogen;

R^{26A} and R^{27A} are independently -C≡N or an optionally substituted substituent selected from the group consisting of C_{2-8} organylcarbonyl, C_{2-8} alkoxycarbonyl and C_{2-8} organylaminocarbonyl;

R^{28A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

R^{30A} and R^{31A} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24}-alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl;

for Formula (III), ------- is a single bond or a double bond;

when ------- is a single bond, each R^{7C} and each R^{8C} is independently hydrogen or halogen; and

when ------- is a double bond, each R^{7C} is absent and each R^{8C} is independently hydrogen or halogen;

$R^{"A}$ and $R^{"C}$ are independently an optionally substituted C_{1-24}-alkyl;


m and n are independently 0 or 1;

p and q are independently selected from the group consisting of 1, 2 and 3;

r is 1 or 2;

Z^{1A}, Z^{2A}, Z^{3A}, Z^{4A}, Z^{1B}, Z^{2B} and Z^{1C} are independently O or S; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is



wherein R^{8A} is an unsubstituted C_{1-4} alkyl or phenyl optionally para-substituted with a halogen or methyl and R^{9A} is methyl ester, ethyl ester, isopropyl ester, n-butyl ester, benzyl ester or phenyl ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro or hydrogen; and B^{1A} is an unsubstituted uracil; then R^{2A} cannot be $-OCH_3$;

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be allenyl;

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is hydrogen; and B^{1A} is an unsubstituted thymine; then R^{2A} cannot be C_1 alkyl substituted with an N-amido; and

provided that when the dashed line (------) of Formula (I) is absent; R^{1A} is H; R^{3A} is OH; R^{4A} is fluoro; R^{5A} is fluoro; and B^{1A} is an unsubstituted cytosine; then R^{2A} cannot be ethynyl.

2. The use of Claim 1, wherein the virus is a henipavirus, a morbillivirus and/or a rubulavirus.

3. The use of Claim 2, wherein the henipavirus is a nipahvirus; wherein the morbillivirus is the measles virus; and/or wherein the rubulavirus is the mumps virus.

4. The use of Claim 1, wherein the virus is a respirovirus.

5. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 1.

6. The use of Claim 4, wherein the respirovirus is human parainfluenza virus 3.




7. The use of Claim 1, wherein the virus is a rubulavirus.

8. The use of Claim 7, wherein the rubulavirus is human parainfluenza virus 2 and/or human parainfluenza virus 4.




9. The use of Claim 1, wherein the virus is a metapneumovirus.




10. The use of Claim 9, wherein the metaphenumovirus is human metapneumovirus.







11. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (I).


12. The use of Claim 11, wherein R^{1A} is  ,  or  .


13. The use of Claim 12, wherein R^{6A} and R^{7A} are both hydrogen or absent.





14. The use of Claim 12, wherein one of R^{6A} and R^{7A} is hydrogen, and the other of R^{6A} and R^{7A} is selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl); wherein both R^{6A} and R^{7A} are independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl); wherein at least one of R^{6A} and R^{7A} are selected from the group consisting of  ,  , and  ; and the other of R^{6A} and R^{7A} is selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_{3-6} cycloalkenyl, an optionally substituted aryl, an




optionally substituted heteroaryl and an optionally substituted aryl(C_{1-6} alkyl); wherein both R^{6A} and R^{7A} are independently selected from the group consisting of  ,  and  ; wherein R^{6A} and R^{7A} are both an optionally substituted C_{1-24} alkyl; wherein R^{6A} and R^{7A} are both an optionally substituted C_{2-24} alkenyl; wherein R^{6A} and R^{7A} are both *–$(CR^{15A}R^{16A})_p$–O–C_{1-24} alkyl; wherein R^{6A} and R^{7A} are both *–$(CR^{17A}R^{18A})_q$–O–C_{2-24} alkenyl; wherein R^{6A} and R^{7A} are both an optionally substituted aryl; or wherein R^{6A} and R^{7A} are both an optionally substituted aryl(C_{1-6} alkyl).




15. The use of Claim 12, wherein R^{6A} and R^{7A} are both  ; wherein R^{6A} and R^{7A} are both  ; wherein R^{6A} and R^{7A} are both  ; wherein R^{6A} and R^{7A} are both  ; wherein R^{6A} and R^{7A} are both  ; or wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of an optionally substituted  and an optionally





substituted  , wherein the oxygens connected to R^{6A} and R^{7A}, the phosphorus and the moiety form a six-membered to ten-membered ring system.

16. The use of Claim 15, wherein  is selected from the group consisting of:

 ,  ,  ,  ,

 ,  ,  ,

 and  or wherein R^{6A} and R^{7A} can be taken together to form a moiety selected from the group consisting of  ,



,

,

and

,

wherein R^{32A} is an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

17. The use of any one of Claims 12-16, wherein Z^{1A} is O.

18. The use of any one of Claims 12-16, wherein Z^{1A} is S.

19. The use of Claim 12, wherein R^{8A} is selected from the group consisting of absent, hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl; and R^{9A} is independently selected from the group consisting of an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl; wherein R^{8A} is hydrogen, and R^{9A} is $NR^{30A}R^{31A}$, wherein R^{30} and R^{31} are independently selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, an optionally substituted C_{2-24} alkenyl, an optionally substituted C_{2-24} alkynyl, an optionally substituted C_{3-6} cycloalkyl and an optionally substituted C_{3-6} cycloalkenyl; wherein R^{8A} is absent or hydrogen; and R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; or wherein R^{8A} is an optionally substituted aryl; and R^{9A} is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

20. The use of Claim 12, wherein R^{9A} is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; or wherein R^{9A} is selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein R^{9A} has the structure  wherein R^{33A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6}


cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{34A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{35A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{34A} and R^{35A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

21. The use of Claim 20, wherein R^{34A} is an optionally substituted C_{1-6}-alkyl; R^{35A} is hydrogen; and/or R^{33A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

22. The use of any one of Claims 12 or 19-21, wherein Z^{2A} is O.

23. The use of any one of Claims 12 or 19-21, wherein Z^{2A} is S.

24. The use of Claim 12, wherein R^{10A} and R^{11A} are both an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; wherein R^{10A} and R^{11A} are independently selected from selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine and ester derivatives thereof; wherein R^{10A} and R^{11A} are independently selected from the group consisting of alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester; or wherein R^{10A} and R^{11A} are independently have the structure




wherein R^{36A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_{1-6} alkyl) and an optionally substituted haloalkyl; R^{37A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{38A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{37A} and R^{38A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

25. The use of Claim 24, wherein R^{37A} is an optionally substituted C_{1-6}-alkyl; R^{38A} is hydrogen and/or R^{36A} is an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-6} cycloalkyl or an optionally substituted benzyl.

26. The use of any one of Claims 12 or 24-25, wherein Z^{3A} is O.

27. The use of any one of Claims 12 or 24-25, wherein Z^{3A} is S.

28. The use of Claim 12, wherein R^{6A} is  and R^{7A} is absent or hydrogen; wherein R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.


29. The use of Claim 28, wherein m is 0, and R^{12A} and R^{13A} are independently absent or hydrogen; or wherein m is 1, and R^{12A}, R^{13A} and R^{14A} are independently absent or hydrogen.

30. The use of Claim 11, wherein R^{1A} is H.

31. The use of Claim 11, wherein R^{1A} is an optionally substituted acyl.







32. The use of Claim 31, wherein the optionally substituted acyl is $-C(=O)R^{39A}$, wherein R^{39A} is selected from the group consisting of an optionally substituted C_{1-12} alkyl, an optionally substituted C_{2-12} alkenyl, an optionally substituted C_{2-12} alkynyl, an optionally substituted C_{3-8} cycloalkyl, an optionally substituted C_{5-8} cycloalkenyl, an optionally substituted C_{6-10} aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_{1-6} alkyl), an optionally substituted heteroaryl(C_{1-6} alkyl) and an optionally substituted heterocyclyl(C_{1-6} alkyl).

33. The use of Claim 32, wherein R^{39A} is an unsubstituted C_{1-12} alkyl.

34. The use of Claim 11, wherein R^{1A} is an optionally substituted O-linked amino acid; or wherein R^{1A} is  , wherein R^{40A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{41A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{40A} and R^{41A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

35. The use of Claim 34, wherein R^{40A} is an optionally substituted C_{1-6}-alkyl; and/or R^{41A} is hydrogen.

36. The use of any one of Claims 11-35, wherein B^{1A} is selected from the group consisting of:


,

,

,

,

and

;

wherein:

R^{A2} is selected from the group consisting of hydrogen, halogen and NHR^{J2}, wherein R^{J2} is selected from the group consisting of hydrogen, $-C(=O)R^{K2}$ and $-C(=O)OR^{L2}$;

R^{B2} is halogen or NHR^{W2}, wherein R^{W2} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{M2}$ and $-C(=O)OR^{N2}$;

R^{C2} is hydrogen or NHR^{O2}, wherein R^{O2} is selected from the group consisting of hydrogen, $-C(=O)R^{P2}$ and $-C(=O)OR^{Q2}$;

R^{D2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;

R^{E2} is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, $-C(=O)R^{R2}$ and $-C(=O)OR^{S2}$;




R^{F2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}alkyl, an optionally substituted C_{2-6} alkenyl and an optionally substituted C_{2-6} alkynyl;



Y^2 and Y^3 are independently N or CR^{I2}, wherein R^{I2} is selected from the group consisting of hydrogen, halogen, an optionally substituted C_{1-6}-alkyl, an optionally substituted C_{2-6}-alkenyl and an optionally substituted C_{2-6}-alkynyl;


R^{G2} is an optionally substituted C_{1-6} alkyl;

R^{H2} is hydrogen or NHR^{T2}, wherein R^{T2} is independently selected from the group consisting of hydrogen, $-C(=O)R^{U2}$ and $-C(=O)OR^{V2}$; and

R^{K2}, R^{L2}, R^{M2}, R^{N2}, R^{P2}, R^{Q2} R^{R2}, $R^{S2,}$ R^{U2} and R^{V2} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, C_{6-10} aryl, heteroaryl, heteroalicyclyl, aryl(C_{1-6} alkyl), heteroaryl(C_{1-6} alkyl) and heteroalicyclyl(C_{1-6} alkyl).

37. The use of Claim 36, wherein B^{1A} is  ;  or  .

38. The use of Claim 36, wherein B^{1A} is  .or 

39. The use of Claim 36, wherein B^{1A} is  .

40. The use of any one of Claims 11-39, wherein the dashed line (------) is absent, R^{2A} is selected from the group consisting of an optionally substituted C_{1-6} alkyl, an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted –O–C_{1-6} alkyl, an optionally substituted –O–C_{3-6} alkenyl, an optionally substituted –O–C_{3-6} alkynyl and cyano, and R^{3A} is selected from the group consisting of OH, -OC(=O)$R^{"A}$ and an optionally substituted O-linked amino acid.

41. The use of Claim 40, wherein R^{2A} is an optionally substituted C_{1-6} alkyl.

42. The use of Claim 41, wherein R^{2A} is a halogen substituted C_{1-6} alkyl, a hydroxy substituted C_{1-6} alkyl, an alkoxy substituted C_{1-6} alkyl or a sulfenyl substituted C_{1-6} alkyl.


43. The use of Claim 41, wherein R^{2A} is a halogen substituted C_{1-6} alkyl.

44. The use of Claim 40, wherein R^{2A} is an optionally substituted C_{2-6} alkenyl, an optionally substituted C_{2-6} alkynyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted –O–C_{1-6} alkyl, an optionally substituted –O–C_{3-6} alkenyl, an optionally substituted –O–C_{3-6} alkynyl or cyano.

45. The use of any one of Claims 11-44, wherein R^{3A} is OH.

46. The use of any one of Claims 11-44, wherein R^{3A} is –OC(=O)$R^{"A}$, wherein $R^{"A}$ is an optionally substituted C_{1-8} alkyl.

47. The use of any one of Claims 11-44, wherein R^{3A} is O-linked amino acid.

48. The use of Claim 47, wherein the O-linked amino acid is selected from the group consisting of alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine; or wherein R^{3A} is 

, wherein R^{42A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{1-6} haloalkyl, an optionally substituted C_{3-6} cycloalkyl, an optionally substituted C_6 aryl, an optionally substituted C_{10} aryl and an optionally substituted aryl(C_{1-6} alkyl); and R^{43A} is hydrogen or an optionally substituted C_{1-4}-alkyl; or R^{42A} and R^{43A} are taken together to form an optionally substituted C_{3-6} cycloalkyl.

49. The use of Claim 48, wherein R^{42A} is an optionally substituted C_{1-6}-alkyl; and/or R^{43A} is hydrogen.

50. The use of any one of Claims 11-49, wherein R^{5A} is hydrogen.


51. The use of any one of Claims 11-49, wherein R^{5A} is halogen.











52. The use of any one of Claims 11-51, wherein R^{4A} is fluoro.

53. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (II).

54. The use of any one of Claims 1-10, wherein the compound is a compound of Formula (III).








55. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:



















and

, or a pharmaceutically acceptable salt of the foregoing.


56. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:


HO
HO
F
N
N
N
N
O
NH2
,

HO
HO
F
N
O

HO
HO
F
N
N
N
N
O
NH2
,

NH2
HO
Cl
HO
F
N

O
NH2






NH2
N
N
O
HO
O
Cl
F
O
O













,














NH2
N
HO
O
O
HO
F


NH2


NH














O
N
N
N
N
NH2
HO
O
HO
F
,

N
N
HO
O
Cl
HO
F

NH2
N
N
N
HO
O
F
HO
F
,

O
NH
N
N
N
HO
O
Cl
HO
F







,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,





,


,



,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.


57. The use of Claim 11, wherein the compound of Formula (I) is selected from the group consisting of:



,

,

,

,


















,








,

,

,

,

,

,

,

,


,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.

58. The use of Claim 11, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

59. The use of Claim 58, wherein the compound of Formula (I) is




, or a pharmaceutically acceptable salt thereof.

60. The use of Claim 58, wherein the compound of Formula (I) is











, or a pharmaceutically acceptable salt thereof.








61. The use of Claim 58, wherein the compound of Formula (I) is



, or a pharmaceutically acceptable salt thereof.

62. The use of Claim 53, wherein the compound of Formula (II) is  ,  ,  and , or a pharmaceutically acceptable salt thereof.

63. The use of Claim 54, wherein the compound of Formula (III) is selected from the group consisting of:  ,  ,  ,  ,  ,


,

,

,

,

,

and

, or a pharmaceutically acceptable salt of the foregoing.